What’s the current market cap for REGENXBIO stock?

REGENXBIO (RGNX) has a market cap of $356M as of May 29, 2026.

What is the P/E ratio for REGENXBIO stock?

The price to earnings (P/E) ratio for REGENXBIO (RGNX) stock is 0 as of May 29, 2026.

Does REGENXBIO stock pay dividends?

No, REGENXBIO (RGNX) stock does not pay dividends to its shareholders as of May 29, 2026.

When is the next REGENXBIO dividend payment date?

REGENXBIO (RGNX) stock does not pay dividends to its shareholders.

What is the beta indicator for REGENXBIO?

REGENXBIO (RGNX) has a beta rating of 1.12. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy REGENXBIO stock | $RGNX Share Price

13:30

15:10

16:45

18:25

20:00

About REGENXBIO

Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.

Ticker

$RGNX

Sector

Health

Primary listing

NASDAQ

Employees

371

Headquarters

Rockville, United States

Website

www.regenxbio.com

REGENXBIO Metrics

BasicAdvanced

$356m

-$5.60

1.12

What the Analysts think about REGENXBIO

Analyst ratings (Buy, Hold, Sell) for REGENXBIO stock.

Bulls say / Bears say

Experimental gene therapy RGX-202 achieved the primary endpoint in the pivotal Phase III AFFINITY DUCHENNE trial, with 93% of patients reaching targeted microdystrophin expression at 12 weeks, confirming its efficacy. (Reuters)

REGENXBIO announced new positive interim results from the Phase I/II AFFINITY DUCHENNE trial for RGX-202, reporting no serious adverse events, and remains on schedule to release pivotal topline data in Q2 2026 ahead of a planned pre-BLA meeting with the FDA in mid-2026. (Reuters)

The FDA removed the partial clinical hold on RGX-121 for MPS II on April 30, 2026, enabling the company to resume its rare disease program. (Nippon Shinyaku)

REGENXBIO reported a net loss of $90.1 million for Q1 2026, compared to net income of $6.1 million in Q1 2025, highlighting significant financial underperformance. (Associated Press)

The FDA issued a Complete Response Letter for the RGX-121 BLA on February 7, 2026, causing delays in the MPS II gene therapy program and requiring the submission of additional data. (SEC Filing)

Cash, cash equivalents and marketable securities amounted to $150.5 million as of March 31, 2026, expected to fund the company only into early 2027, casting serious doubt over REGENXBIO’s ability to continue operating without new financing. (SEC Filing)

Data summarised monthly by Lightyear AI. Last updated on 28 May 2026.

REGENXBIO Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

REGENXBIO Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RGNX

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

The FDA removed the partial clinical hold on RGX-121 for MPS II on April 30, 2026, enabling the company to resume its rare disease program. (Nippon Shinyaku)

REGENXBIO reported a net loss of $90.1 million for Q1 2026, compared to net income of $6.1 million in Q1 2025, highlighting significant financial underperformance. (Associated Press)

The FDA issued a Complete Response Letter for the RGX-121 BLA on February 7, 2026, causing delays in the MPS II gene therapy program and requiring the submission of additional data. (SEC Filing)

Data summarised monthly by Lightyear AI. Last updated on 28 May 2026.